Cumberland Pharmaceuticals (CPIX) executive compensation, 2026 proxy

A.J. Kazimi, Chairman and Chief Executive Officer, was paid $1.6M in 2025, up 34% from $1.2M the year before. The CEO-to-median-employee pay ratio was 10:1, on median employee pay of $101,000.

Filed
March 9, 2026
Annual meeting
April 21, 2026
Pay year
2025
Named executives
5
CEO total pay
$1.6M+34% vs prior year
CEO to median employee
10:1median $101,000
CEO Total Compensation
$1,558,849For fiscal year 2025
CEO Pay Ratio
10:1Compared to median employee
Median Employee Pay
$101,000Annual total compensation
CEO Salary
$730,080Base salary for 2025
Total Employees
93Determined as of year end

How Kazimi was paid

$1.6M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary47%Bonus16%Option awards37%Pension and deferred comp1%All other compensation0%

Named executive officers

ExecutiveTotal
A.J. KazimiChairman and Chief Executive Officer$1,558,849
Todd M. AnthonyVice President Organizational Development$355,605
John M. HammVice President and Chief Financial Officer$312,442
Chris T. BittermanVice President Sales and Marketing$322,480
James L. HermanVice President Trade and Distribution$224,735

What changed and why

  • $1.6MChief Executive Officer total compensation increased to $1,558,849 for fiscal year 2025.
  • $569KOption awards granted to the Chief Executive Officer were valued at $569,000 in 2025.
  • The ratio of annual total compensation of the Chief Executive Officer to the median employee was 10:1.
  • The company examined its payroll records for 93 total employees to determine median compensation.
  • Life insurance premiums and deferred contribution plan additions were provided as other compensation components.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.